CR20150642A - Preparado farmaceutico - Google Patents
Preparado farmaceuticoInfo
- Publication number
- CR20150642A CR20150642A CR20150642A CR20150642A CR20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A CR 20150642 A CR20150642 A CR 20150642A
- Authority
- CR
- Costa Rica
- Prior art keywords
- solution
- child
- pharmaceutical preparation
- alpha emitting
- selective binder
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 3
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- Saccharide Compounds (AREA)
- Extraction Or Liquid Replacement (AREA)
Abstract
Un método para generar una solución purificada de por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto una solución del complejo de radionúclido emisor alfa y por lo menos un núclido hijo que tiene por lo menos un ligante selectivo para los núclidos hijos y subsiguientemente separar la solución del ligante selectivo. También, un método para separar por lo menos un radionúclido hijo de una solución que comprende por lo menos un complejo de radionúclido emisor alfa. El método comprende poner en contacto la solución que tiene por lo menos un ligante selectivo para los núclidos hijos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1310028.4A GB201310028D0 (en) | 2013-06-05 | 2013-06-05 | Pharmaceutical preparation |
| PCT/EP2014/061743 WO2014195423A1 (en) | 2013-06-05 | 2014-06-05 | Pharmaceutical preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150642A true CR20150642A (es) | 2016-07-22 |
Family
ID=48805787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150642A CR20150642A (es) | 2013-06-05 | 2015-12-04 | Preparado farmaceutico |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US20160114063A1 (es) |
| EP (1) | EP3003401B1 (es) |
| JP (1) | JP6580559B2 (es) |
| KR (1) | KR102321763B1 (es) |
| CN (1) | CN105592863B (es) |
| AP (1) | AP2015008894A0 (es) |
| AU (1) | AU2014276885B2 (es) |
| BR (1) | BR112015030298A2 (es) |
| CA (1) | CA2914278C (es) |
| CL (1) | CL2015003554A1 (es) |
| CR (1) | CR20150642A (es) |
| CU (1) | CU24535B1 (es) |
| DK (1) | DK3003401T3 (es) |
| DO (1) | DOP2015000294A (es) |
| EA (1) | EA201501174A1 (es) |
| ES (1) | ES2782624T3 (es) |
| GB (1) | GB201310028D0 (es) |
| HR (1) | HRP20200456T1 (es) |
| IL (1) | IL242704B (es) |
| LT (1) | LT3003401T (es) |
| MA (1) | MA38650B1 (es) |
| MX (1) | MX366028B (es) |
| MY (1) | MY180717A (es) |
| NI (1) | NI201500173A (es) |
| PE (1) | PE20160215A1 (es) |
| PH (1) | PH12015502715B1 (es) |
| PL (1) | PL3003401T3 (es) |
| PT (1) | PT3003401T (es) |
| RS (1) | RS60091B1 (es) |
| SA (1) | SA515370233B1 (es) |
| SG (1) | SG11201509856RA (es) |
| SI (1) | SI3003401T1 (es) |
| TN (1) | TN2015000527A1 (es) |
| UA (1) | UA120352C2 (es) |
| WO (1) | WO2014195423A1 (es) |
| ZA (1) | ZA201600027B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201600158D0 (en) * | 2016-01-05 | 2016-02-17 | Bayer As | Purification method |
| GB201600161D0 (en) | 2016-01-05 | 2016-02-17 | Bayer As | Isotope purification method |
| CN114902350A (zh) | 2019-12-05 | 2022-08-12 | 塞控斯公司 | 生产高纯度212Pb |
| AU2022210371A1 (en) | 2021-01-22 | 2023-07-20 | Bayer Aktiengesellschaft | Lrrc15 antibodies and conjugates thereof |
| NO347755B1 (en) * | 2021-10-21 | 2024-03-18 | Blue Wave Therapeutics Gmbh | Peptide-coupled alginate gels comprising radionuclides |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5749042A (en) * | 1997-01-28 | 1998-05-05 | Battelle Memorial Institute | Bismuth generator method |
| GB0308731D0 (en) | 2003-04-15 | 2003-05-21 | Anticancer Therapeutic Inv Sa | Method of radiotherapy |
| US8481694B2 (en) * | 2009-04-29 | 2013-07-09 | Bio-Rad Laboratories, Inc. | Purification of immunoconjugates |
| GB201002508D0 (en) | 2010-02-12 | 2010-03-31 | Algeta As | Product |
| GB201105298D0 (en) * | 2011-03-29 | 2011-05-11 | Algeta Asa | Pharmaceutical preparation |
-
2013
- 2013-06-05 GB GBGB1310028.4A patent/GB201310028D0/en not_active Ceased
-
2014
- 2014-06-05 ES ES14728571T patent/ES2782624T3/es active Active
- 2014-06-05 TN TN2015000527A patent/TN2015000527A1/en unknown
- 2014-06-05 CN CN201480044621.8A patent/CN105592863B/zh not_active Expired - Fee Related
- 2014-06-05 LT LTEP14728571.2T patent/LT3003401T/lt unknown
- 2014-06-05 BR BR112015030298A patent/BR112015030298A2/pt active Search and Examination
- 2014-06-05 SI SI201431535T patent/SI3003401T1/sl unknown
- 2014-06-05 CU CU2015000174A patent/CU24535B1/es unknown
- 2014-06-05 EA EA201501174A patent/EA201501174A1/ru unknown
- 2014-06-05 AU AU2014276885A patent/AU2014276885B2/en not_active Ceased
- 2014-06-05 PE PE2015002566A patent/PE20160215A1/es unknown
- 2014-06-05 KR KR1020157036893A patent/KR102321763B1/ko not_active Expired - Fee Related
- 2014-06-05 HR HRP20200456TT patent/HRP20200456T1/hr unknown
- 2014-06-05 WO PCT/EP2014/061743 patent/WO2014195423A1/en not_active Ceased
- 2014-06-05 UA UAA201512920A patent/UA120352C2/uk unknown
- 2014-06-05 RS RS20200349A patent/RS60091B1/sr unknown
- 2014-06-05 PT PT147285712T patent/PT3003401T/pt unknown
- 2014-06-05 MA MA38650A patent/MA38650B1/fr unknown
- 2014-06-05 SG SG11201509856RA patent/SG11201509856RA/en unknown
- 2014-06-05 DK DK14728571.2T patent/DK3003401T3/da active
- 2014-06-05 AP AP2015008894A patent/AP2015008894A0/xx unknown
- 2014-06-05 US US14/896,424 patent/US20160114063A1/en not_active Abandoned
- 2014-06-05 MX MX2015016726A patent/MX366028B/es active IP Right Grant
- 2014-06-05 MY MYPI2015704399A patent/MY180717A/en unknown
- 2014-06-05 PL PL14728571T patent/PL3003401T3/pl unknown
- 2014-06-05 JP JP2016517608A patent/JP6580559B2/ja not_active Expired - Fee Related
- 2014-06-05 CA CA2914278A patent/CA2914278C/en active Active
- 2014-06-05 EP EP14728571.2A patent/EP3003401B1/en active Active
-
2015
- 2015-11-22 IL IL242704A patent/IL242704B/en active IP Right Grant
- 2015-12-03 SA SA515370233A patent/SA515370233B1/ar unknown
- 2015-12-04 PH PH12015502715A patent/PH12015502715B1/en unknown
- 2015-12-04 DO DO2015000294A patent/DOP2015000294A/es unknown
- 2015-12-04 CL CL2015003554A patent/CL2015003554A1/es unknown
- 2015-12-04 CR CR20150642A patent/CR20150642A/es unknown
- 2015-12-04 NI NI201500173A patent/NI201500173A/es unknown
-
2016
- 2016-01-04 ZA ZA2016/00027A patent/ZA201600027B/en unknown
-
2021
- 2021-05-04 US US17/307,857 patent/US20220023449A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18053055A (es) | Agonista triple de receptores de glucagón/glp-1/gip | |
| DOP2015000261A (es) | Compuesto peptídico como activador de los receptores del glp-1 y del gip | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| ECSP17010156A (es) | Compuestos aminopirimidinilo como inhibidores jak | |
| CL2018000088A1 (es) | Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen | |
| CL2017003205A1 (es) | Nuevos derivados bicíclicos, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
| MX2018009876A (es) | Encapsulamiento y desencapsulamiento de medios. | |
| NI201700167A (es) | Terapias combinadas para hemo malignidades con anticuerpos anti-cd38 e inhibidores de survivina | |
| CR20150049A (es) | Anticuerpos e inmunoconjugados anti-cd79b | |
| MX2017001512A (es) | Compuestos activos hacia bromodominios. | |
| AR115788A2 (es) | Dispositivos de decodificación y codificación, y método de codificación, en un sistema de audio de canales múltiples | |
| CL2018000087A1 (es) | Métodos para fabricar un compuesto elastómero reforzado con sílice y productos que lo contienen | |
| CL2018000371A1 (es) | Complejos de anillos macrocíclicos de pentaaza que poseen biodisponibilidad oral. | |
| CR20150642A (es) | Preparado farmaceutico | |
| CL2016000032A1 (es) | Sistema de acoplamiento de un elemento auxiliar en una silla de ruedas | |
| CU20160069A7 (es) | Sistema multiparticulado para administrar drogas | |
| EA201890828A1 (ru) | Оптимизированная таблетка с высокой дозой активного соединения, содержащая месалазин | |
| CL2015002358A1 (es) | Compuestos bicíclicos. | |
| ZA201606375B (en) | Machine for generating unstructured syntax | |
| BR112017002139A2 (pt) | ?método para preparar um composto? | |
| UY35823A (es) | Profármacos de antagonista de nmda | |
| CR20140051A (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
| MX2019015603A (es) | Encapsulamiento de guia de servicios. | |
| FR3025354B1 (fr) | Creation d'isotopes par reactions nucleaires en chaine | |
| AR096678A1 (es) | Moduladores de los receptores de estrógeno y sus usos |